What are Cytek Biosciences, Inc.'s total assets?

Cytek Biosciences, Inc. (CTKB) holds $449.1M in total assets, down 6.9% year over year.

How much debt does Cytek Biosciences, Inc. have?

Cytek Biosciences, Inc. carries $16.8M in total debt against $327.6M of shareholders' equity, a debt-to-equity ratio of 0.05.

How much cash does Cytek Biosciences, Inc. have?

Cytek Biosciences, Inc. holds $31.8M in cash and equivalents.

Can Cytek Biosciences, Inc. cover its short-term obligations?

Its current ratio is 4.69 — current assets exceed current liabilities.

Where does Cytek Biosciences, Inc.'s balance sheet data come from?

Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Cytek Biosciences, Inc. CTKB Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$31.81M-66.6%	$28.98M-70.6%	$93.28M-42.5%	$75.47M-57.6%	$95.3M-43.5%
Accounts receivable, net	$51.9M-5.7%	$62.51M+3.2%	$56.63M+7.6%	$56.23M+26.0%	$55.03M+9.4%
Inventories	$49.79M+9.8%	$48.43M+10.3%	$51.65M+10.4%	$49.49M-1.2%	$45.35M-17.2%
Raw materials	$23.64M—	$20.44M—	——	——	——
Work in process	$16.34M—	$16.53M—	——	——	——
Finished goods	$9.81M—	$11.46M—	——	——	——
Prepaid expenses and other current assets	$15.38M+6.0%	$19.53M+38.8%	$18.47M+42.7%	$15.08M+24.4%	$14.51M+10.3%
Income taxes receivable	$2.77M—	$2.79M—	——	——	——
Total current assets	$379.3M-0.3%	$392M-1.1%	$388.49M-0.4%	$382.83M-0.3%	$380.5M-2.1%
Property and equipment, net	$20.47M+14.8%	$18.01M+0.3%	$18.05M-2.5%	$18.35M+1.3%	$17.83M-2.3%
Accumulated depreciation	$13.06M—	$12.13M—	——	——	——
Operating lease right-of-use assets	4.5%-986,899,996%	4.5%-1,016,799,996%	1,115,800,000%+103,400,000%	1,638,700,000%+705,900,000%	986,900,000%-8,000,000%
Goodwill	$16.69M+0.1%	$16.7M+0.2%	$16.7M+3.2%	$16.71M+3.2%	$16.68M+3.1%
Intangible assets, net	$15.7M-19.2%	$16.82M-16.4%	$17.68M-13.7%	$18.6M-13.2%	$19.43M-12.7%
Deferred tax assets	-$183K-101%	$0-100%	$38.39M+24.7%	$35.77M+20.5%	$33.71M+3.1%
Other non-current assets	$6.31M+37.9%	$6.7M+40.9%	$4.46M-9.9%	$4.68M-4.8%	$4.57M+12.1%
Equity method investments	$1.6M—	——	——	——	——
Total investment securities	$196.56M—	$170.68M—	——	——	——
Total assets	$449.11M-6.9%	$461.54M-7.6%	$494.92M+0.8%	$493.32M+2.0%	$482.6M-1.9%
Accounts payable	$6.74M+7.9%	$6.41M+15.9%	$7.63M+41.6%	$6.85M+115%	$6.25M+67.7%
Accrued expenses	$22.17M+72.7%	$16.98M+25.8%	$16.43M+86.4%	$14.72M+104%	$12.84M+56.0%
Accrued compensation	$8.07M—	$15.19M—	——	——	——
Deferred revenue	$30.03M+91.1%	$28.5M+77.1%	$16.32M+10.3%	$16.63M+18.2%	$15.72M+3.6%
Operating lease liabilities, current	$2.94M-16.8%	$2.88M-23.3%	$3.09M-12.4%	$3.33M+38.1%	$3.54M+55.2%
Contract liabilities	$17.67M—	$18.34M—	——	——	——
Income taxes payable	$3.8M—	$3.07M—	——	——	——
Total current liabilities	$80.94M+19.6%	$77.8M+15.0%	$75.21M+19.8%	$73.27M+39.9%	$67.69M+21.8%
Long-term debt	$386K-58.0%	$525K-50.0%	$655K-47.0%	$791K-40.5%	$918K-37.8%
Operating lease liabilities, non-current	$13.44M+80.5%	$14.04M+85.9%	$13.49M+74.0%	$14.12M+74.0%	$7.45M-14.4%
Operating Lease Liabilities (Total)	$16.39M+49.1%	$16.92M+49.6%	$16.59M+47.0%	$17.44M+65.8%	$10.99M+0.1%
Other non-current liabilities	$2.4M+0.8%	$2.31M-2.4%	$2.52M+18.8%	$2.48M+37.5%	$2.38M+30.3%
Total liabilities	$121.47M+18.0%	$119.8M+15.5%	$116.35M+10.0%	$115.76M+22.4%	$102.97M+3.5%
Common stock	1B+781,150%	1B+775,094%	128K-1.5%	127K-3.8%	128K-2.3%
Additional paid-in capital	$445.75M+4.5%	$441.11M+2.4%	$435.28M+1.2%	$429.65M-1.2%	$426.71M-0.6%
Retained earnings	-$120.6M-159%	-$101.74M-189%	-$57.66M-28.6%	-$52.18M-14.0%	-$46.6M-31.8%
Accumulated other comprehensive income (loss)	$2.37M+489%	$2.24M+13,906%	$821K+713%	-$38K+80.5%	-$609K+60.8%
Total stockholders' equity	$327.64M-13.7%	$341.74M-13.6%	$378.57M-1.8%	$377.56M-3.0%	$379.62M-3.3%
Total liabilities and stockholders' equity	$449.11M-6.9%	$461.54M-7.6%	$494.92M+0.8%	$493.32M+2.0%	$482.6M-1.9%
Available-for-Sale Debt Securities - Amortized Cost	$196.62M—	$170.54M—	——	——	——
Allowance for Doubtful Accounts	$1.18M—	$729K—	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	$1.18M—	$729K—	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$196.56M—	$170.68M—	——	——	——
Other current assets	$3.6M—	$2.98M—	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$6.31M+37.9%	$6.7M+40.9%	$4.46M-9.9%	$4.68M-4.8%	$4.57M+12.1%
Finite Lived Intangible Assets - Gross	$28.53M—	$28.89M—	——	——	——
Investments - Amortized Cost Basis	$196.62M—	$170.54M—	——	——	——
Net Investment in Lease	$10.64M+7.8%	$11.32M+11.3%	$11.16M+10.2%	$16.39M+75.7%	$9.87M-0.8%
Intangible assets — net	$15.7M—	$16.82M—	——	——	——
Other intangible assets—net	$15.7M-19.2%	$16.82M-16.4%	$17.68M-13.7%	$18.6M-13.2%	$19.43M-12.7%
Operating lease right-of-use assets	$10.64M+7.8%	$11.32M+11.3%	$11.16M+10.2%	$16.39M+75.7%	$9.87M-0.8%
Other non-current assets	$6.31M+37.9%	$6.7M+40.9%	$4.46M-9.9%	$4.68M-4.8%	$4.57M+12.1%
Property, plant and equipment at cost	$33.53M—	$30.14M—	——	——	——
Tenant Improvements	$3.56M—	$4.21M—	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$10.64M+7.8%	$11.32M+11.3%	$11.16M+10.2%	$16.39M+75.7%	$9.87M-0.8%
Software and Technology Licenses, Net	$6.31M+37.9%	$6.7M+40.9%	$4.46M-9.9%	$4.68M-4.8%	$4.57M+12.1%
Accrued Litigation	$6.64M-24.7%	$6.79M-24.9%	$8.16M-52.2%	$8.48M-49.9%	$8.82M-47.3%
Accrued Progress Collections and Price Adjustments	$17.67M—	$18.34M—	——	——	——
Other Commercial Liabilities	$19.78M+3.0%	$23.42M+9.2%	$20.23M-2.4%	$21.6M+39.5%	$19.2M+6.3%
Accounts payable and other current liabilities (Note 11)	$19.78M—	$23.42M—	——	——	——
Accrued Income Taxes, Current	$3.8M—	$3.07M—	——	——	——
Accrued Liabilities, Current	$19.78M+3.0%	$23.42M+9.2%	$20.23M-2.4%	$21.6M+39.5%	$19.2M+6.3%
Deferred income	$30.03M+8.4%	$28.5M+11.8%	$28.74M+13.3%	$28.13M+17.4%	$27.71M+20.4%
Other accrued liabilities	$22.17M+72.7%	$16.98M+25.8%	$16.43M+86.4%	$14.72M+104%	$12.84M+56.0%
Current portion of accrued product warranty	$1.43M—	$1.46M—	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	$2.69M—	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	$3.5M—	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$1.39M—	——	——	——	——
Lease Liability Payments - Due Year Two	$3.5M—	——	——	——	——
Lease Liability Payments - Due Year Three	$1.83M—	——	——	——	——
Lease Liability Payments - Due Year Four	$1.39M—	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$3.96M—	——	——	——	——
Operating Lease Liability Payments Due	$20.5M—	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	$4.12M—	——	——	——	——
Professional Service Fees Payable	$5.11M—	$3.31M—	——	——	——
Sales taxes payable	$3.23M—	$3.22M—	——	——	——
Settlement Liabilities (Current)	$2.21M+29.5%	$2.5M+46.3%	$2.18M-12.8%	$1.97M-21.4%	$1.71M-33.1%
Standard Product Warranty Accrual	$1.43M—	$1.46M-18.9%	——	——	——
Contract Liabilities, Non-Current	$17.67M—	$18.34M—	——	——	——
Debt Maturity - 2027	$101K—	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$1.83M—	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$1.83M—	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$1.39M—	——	——	——	——
Deferred revenue, net of current portion	$17.67M—	$18.34M—	——	——	——
Deferred income	$17.67M+12.4%	$18.34M+13.9%	$16.32M+10.3%	$16.63M+18.2%	$15.72M+3.6%
Total debt	$16.77M+40.9%	$17.45M+41.2%	$17.24M+37.7%	$18.24M+53.9%	$11.9M-4.4%
Total Carrying Value of Debt	$386K-58.0%	$525K-50.0%	$655K-47.0%	$791K-40.5%	$918K-37.8%
Common Stock Par Value Per Share	$0.00—	$0.00—	——	——	——
Common Stock Shares Issued	129.1M—	128.6M—	——	——	——
Common Stock Shares Outstanding	$4.22M—	$6.92M—	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$129K+0.8%	$129K0.0%	$128K-1.5%	$127K-3.8%	$128K-2.3%
Number of Exercisable Options	6.2M—	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	10.4M—	9.1M—	——	——	——
Unrealized Gains on Investments	$25K—	$140K—	——	——	——
Unrealized Losses on Investments (Before Tax)	$82K—	$0—	——	——	——
Weighted Average Exercise Price of Outstanding Options	$7.49—	$7.91—	——	——	——
Cumulative Cost Basis	$196.62M—	$170.54M—	——	——	——
Professional service fees	$5.11M—	$3.31M—	——	——	——
Purchases	$2.52M—	$1.84M—	——	——	——
Accounts Receivable, Allowance for Credit Loss	$1.18M—	$729K—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$82K—	$0—	——	——	——
Gross Unrealized Gains	$25K—	$140K—	——	——	——
Total	$196.62M—	$170.54M—	——	——	——
Available for sale investments	$196.56M—	$170.68M—	——	——	——
Cash FDIC Insured Amount	$250K—	——	——	——	——
Common stock, par value (in dollars per share)	$0—	$0—	——	——	——
Common stock, shares authorized (in shares)	$1B—	$1B—	——	——	——
Common stock, shares issued (in shares)	$129.14M—	$128.55M—	——	——	——
Common Stock, Shares, Outstanding	$129.14M—	$128.55M—	——	——	——
Contract with Customer, Liability	$48.85M—	$47.91M—	——	——	——
Beginning balance	——	——	——	——	——
Customer deposits, which are included in 'Other current liabilities'	$1.15M—	$1.07M—	——	——	——
Long-term debt, gross	$386K-58.0%	$525K-50.0%	$655K-47.0%	$791K-40.5%	$918K-37.8%
Equity method investments (Note 11)	$1.6M—	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$12.83M—	$12.07M—	——	——	——
Gross Carrying Amount	$28.53M—	$28.89M—	——	——	——
Raw materials	$23.64M—	$20.44M—	——	——	——
Legal Settlement Liability	$8.85M—	$9.28M—	——	——	——
Legal settlement liability	$2.21M—	$2.5M—	——	——	——
Legal settlement liability	$6.64M—	$6.79M—	——	——	——
Lessee Operating Lease Liability Payments Due	$20.5M—	——	——	——	——
Thereafter	$7.14M—	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$4.12M—	——	——	——	——
Estimated Litigation Liability, Noncurrent	$6.64M-24.7%	$6.79M-24.9%	$8.16M-52.2%	$8.48M-49.9%	$8.82M-47.3%
Current portion of loan and line of credit	$10.71M—	$6.3M—	——	——	——
Marketable Securities	$196.56M—	$170.68M—	——	——	——
Money Market Funds At Carrying Value	$32.91M—	$45.44M—	——	——	——
Long-Lived Assets	$20.47M—	$18.01M—	——	——	——
Number of stock-based compensation plan	3—	——	——	——	——
Number of vote per share	1—	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.05—	$0.05—	——	——	——
Other accrued liabilities	$2.66M—	$1.63M—	——	——	——
Other	$340K—	$451K—	——	——	——
Prepaid Insurance	$559K—	$884K—	——	——	——
Prepaid inventory	$593K—	$228K—	——	——	——
Purchase Obligation	$2.69M—	——	——	——	——
Thereafter	$4K—	——	——	——	——
Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied	$47.7M—	——	——	——	——
Settlement Liabilities, Current	$2.21M+29.5%	$2.5M+46.3%	$2.18M-12.8%	$1.97M-21.4%	$1.71M-33.1%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$6.22M—	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$10.39M—	$9.14M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$7.49—	$7.91—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$4.22M—	$6.92M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$9.13—	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$3.77M—	——	——	——	——
Standard Product Warranty Accrual	$1.43M—	$1.46M-18.9%	——	——	——
Tax Refund Receivable And Payable	$1.02M—	$5.41M—	——	——	——
US Government Securities At Carrying Value	$949K—	$16.43M—	——	——	——
Purchase Commitments - Due Next Year	$1.08M—	——	——	——	——
Purchase Obligation	$2.69M—	——	——	——	——
Remainder of Fiscal Year 2024	$2.69M—	——	——	——	——
Unrecorded Unconditional Purchase Obligation	$1.51M—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Cytek Biosciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Cytek Biosciences, Inc.'s total assets?: Cytek Biosciences, Inc. (CTKB) holds $449.1M in total assets, down 6.9% year over year.
How much debt does Cytek Biosciences, Inc. have?: Cytek Biosciences, Inc. carries $16.8M in total debt against $327.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
How much cash does Cytek Biosciences, Inc. have?: Cytek Biosciences, Inc. holds $31.8M in cash and equivalents.
Can Cytek Biosciences, Inc. cover its short-term obligations?: Its current ratio is 4.69 — current assets exceed current liabilities.
Where does Cytek Biosciences, Inc.'s balance sheet data come from?: Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.